Clinical Trials Logo

Clinical Trial Summary

Succinylcholine is a medication (depolarizing muscle relaxant) that is used as part of an anesthetic (going to sleep for surgery). This medication can cause significant muscle soreness. Rocuronium is a medication (non-depolarizing muscle relaxant) that some anesthesia providers believe may reduce muscle soreness caused by succinylcholine if given prior, but this has been controversial. Some anesthesiologists pretreat patients with rocuronium before giving patients succinylcholine, and some do not. The purpose of this study is to examine the effect of pretreatment with rocuronium on muscle soreness associated with succinylcholine administration.


Clinical Trial Description

After IRB approval from Indiana University Hospital and with written and verbal informed consent from each patient, 300 ASA I, II and III outpatients scheduled for elective Endoscopic Retrograde Cholangiopancreatography (ERCP) under general anesthesia will be enrolled in this randomized-controlled study. The participants and the study personnel performing post-op assessments will be blinded. Anesthesia providers cannot be blinded during this study since anesthesia providers will be required to draw up the study drugs as well as managing the wait time between rocuronium and succinylcholine. Patients are assigned to one of three groups (n = 100 each group). Each participant will undergo a standard IV induction of anesthesia (Lidocaine 1mg/kg, propofol 1-2 mg/kg titrated to effect, and succinylcholine (administered as indicated by study group assignment). Study group details are as follows: Group 1 (Control) to receive no rocuronium pretreatment and 1 mg/kg of succinylcholine. Groups 2 and 3 to receive 0.05 mg/kg up to 5 mg of rocuronium; patients ranged from 50-120 kg. In Group 2, succinylcholine administration will occur at 1.0 mg/kg at t = 1 minute after pretreatment with rocuronium. In Group 3, succinylcholine will be administered (1.0 mg/kg) at t = 2 minutes after pretreatment. The Succinylcholine-induced fasciculations will be noted on study assessment data sheet as either present or absent. . Myalgia assessment is to occur post-succinylcholine administration at t =3 hours and t = 24 hours and will be rated as described below. Myalgia assessment: Participants will by queried at the above time points about muscle pain and scored based on their answers as follows. 0 - no pain /no muscle stiffness 1. - mild muscle pain and/or stiffness at 1 or more sites that does not limit daily activity 2. - Moderate muscle pain and/or stiffness at 1 or more sites that does not limit daily activity 3. - Moderate generalized muscle pain and/or stiffness limiting daily activity 4. - Severe muscle pain and/or stiffness at 1 or more sites limiting movement and preventing daily activity ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04581395
Study type Interventional
Source Indiana University
Contact
Status Completed
Phase Phase 3
Start date October 2, 2020
Completion date April 25, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT02362685 - Metabolic Exercise Testing
Recruiting NCT05033613 - Home Blood Pressure Monitoring Before and After COVID-19 Vaccination in Patients at High Risk of Cardiovascular Disease
Recruiting NCT03849534 - Treatment of Temporomandibular Disorders in Children and Adolsecents N/A
Completed NCT04897581 - BBTI vs PSR in Musculoskeletal Orofacial Pain Adults N/A
Completed NCT00957996 - Safety Study of IV Peramivir in Hospitalized Subjects With Confirmed or Suspected Influenza Phase 3
Completed NCT01026311 - Coenzyme Q10 in Older Athletes Treated With Statin Medications Phase 4
Completed NCT01506583 - Clinical Evaluation of QFlu Combo Test
Completed NCT04797936 - BNO 1030 Extract (Imupret) in the Treatment of Mild Forms of COVID-19 Phase 4
Terminated NCT02685202 - Temporomandibular Disorder (TMD) Pain in Response to Jaw Advancement in People With TMD and Obstructive Sleep Apnea N/A
Completed NCT01279590 - Study of the Safety and Tolerability Associated With PPD10558 Versus Atorvastatin in Patients Previously Intolerant to Statins Due to Statin-associated Myalgia (SAM) Phase 2
Recruiting NCT04806191 - Simple and Evidence-based Examination and Treatment of Shoulder Pain in General Practice N/A
Enrolling by invitation NCT06405646 - Concentration of Receptors With Affinity for Cannabidiol and Cannabinol and the Effect on Chronic Orofacial Pain of Muscle Origin
Not yet recruiting NCT01097798 - To Evaluate the Efficacy and Safety Aliviador Compared to Gelol in Patients With Contusions, Sprains, Trauma and Muscle Injury. Phase 3
Not yet recruiting NCT05961501 - The Effectiveness of CBD and CBN in the Treatment of Facial Pain and Headache of Muscular Origin Phase 2/Phase 3
Completed NCT05448209 - The Effect of Walking Exercise Based on TOUS on Peripheral Neuropathy and Arthralgia-Myalgia in Women With Breast Cancer N/A
Not yet recruiting NCT03566394 - Prophylactic Gabapentin for Taxane-Induced Arthralgia and Myalgia Syndrome in Breast Cancer Patients Undergoing Adjuvant Chemotherapy Phase 2/Phase 3
Not yet recruiting NCT04426123 - Masseter Myofascial Pain Relief Following an Intra-muscular Injection With Botulinum Toxin Type A. Phase 2
Completed NCT04737278 - Safety and Efficacy of Cunermuspir on Energy, Strength, and Fatigue in Patients With Nerve or Muscle Pain Phase 1/Phase 2
Recruiting NCT06125002 - Diosmin for Treatment of Delayed-onset Muscle Soreness (DOMS) Phase 1
Completed NCT03371888 - The Platelet-Rich Plasma in the Therapy of Temporomandibular Disorders Phase 2/Phase 3